The term “cardiac arrhythmia” encompasses disturbances of the normal rhythmic activity of the heart, including both the initiation and the conduction of the impulse. Recent methods of investigation have shown that arrhythmias are common in apparently normal individuals as well as in those with cardiac disease. Understanding arrhythmias and their treatment requires knowledge of the anatomy and electrophysiological properties of the specialised conducting system. Likewise, the selection of an anti-arrhythmic agent demands knowledge of its pharmacological properties, its site of action and its range of anti-arrhythmic activity. Rational therapy depends on establishing the correct diagnosis, which is often difficult since arrhythmias may be paroxysmal rather than sustained and infrequent rather than constant. The diagnosis of an arrhythmia in itself does not necessarily indicate a need for treatment. The decision to treat is influenced by the nature of the arrhythmia, the potential complications and the level of accompanying symptoms.
KeywordsCaffeine Glaucoma Glycoside Propranolol Lidocaine
Unable to display preview. Download preview PDF.
- Conard GJ, Carlson GL, Frost JW, Ober RE, Leon AS, Hunninghake DB (1976) Human plasma elimination kinetics of R818, a new anti-arrhythmic. Proc A Ph A Acad Pharmaceut Sci. Orlando: 106Google Scholar
- Conard GJ, Carlson GL, Frost JW, Ober RE (1979) Human plasma pharmacokinetics of flecainide (R818) a new anti-arrhythmic following single oral and intravenous doses. Clin Pharmacol Ther 25: 218Google Scholar
- Harrison DC, Alderman EL (1972) The pharmacology and clinical use of Lidocaine as an antiarrhythmic drug—1972. Harper and Row, Hagerstown, M.D. (Modern Treatment vol 9)Google Scholar
- Vaughan Williams EM (1970) Classification of antiarrhythmic drugs. In: Sandboe E, Flensted-Jensen KH, Olesen AB (eds) Symposium on cardiac arrhythmias. Astra, Sodertalje, Sweden, pp 449–472Google Scholar
- Winkle RA et al. (1976) Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic Tocainide. Circulation 54: 884–889Google Scholar